Komori
Oiles (6282) · FactAnnual R&D expenditure update

Quarterly R&D expenses: ¥619 million

First written in FY2017-Q1. . Latest entry: FY2026.

34entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q1 – FY20262016: 220162017: 420172018: 420182019: 420192020: 320202021: 320212022: 420222023: 420232024: 320242025: 220252026: 12026
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 204 companies write about · 0 as a headwind · 217 as a tailwind

90 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 219 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Annual R&D expenditure updateAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥2,971 million, or 4.3% of net sales, compared with ¥2,878 million, or 4.3% of net sales, in the previous consolidated fiscal year.」

    Research and development expenses increased by ¥93 million from the previous fiscal year, while the ratio to net sales remained unchanged at 4.3%.
  2. FY2026-H1Update to the six-month cumulative research and development expensesAnnual report

    「The amount of research and development activities for the Group as a whole during the six-month consolidated accounting period was ¥1,482 million.」

    ¥1,482 million has been disclosed as research and development expenses for the six-month consolidated accounting period.
  3. FY2025Annual R&D expenditure updateAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥2,878 million, or 4.3% of net sales, compared with ¥2,529 million, or 3.7% of net sales, in the previous consolidated fiscal year.」

    Research and development expenses were ¥2,878 million, or 4.3% of net sales, with both the amount and the ratio increasing from ¥2,529 million and 3.7%, respectively, in the previous fiscal year.
  4. FY2025-H1Update to the six-month cumulative research and development expensesAnnual report

    「The amount of research and development activities for the Group as a whole during the six-month consolidated accounting period was ¥1,354 million.」

    ¥1,354 million has been disclosed as research and development expenses for the six-month consolidated accounting period.
  5. FY2024Annual R&D expenditure updateAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥2,529 million, or 3.7% of net sales, compared with ¥2,527 million, or 4.0% of net sales, in the previous consolidated fiscal year.」

    Research and development expenses increased to ¥2,529 million, while the ratio to net sales declined from 4.0% to 3.7%.
  6. FY2024-Q3Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the nine-month cumulative consolidated period was ¥1,879 million.」

    ¥1,879 million has been disclosed as research and development expenses for the three-quarter cumulative consolidated period.
  7. FY2024-Q2Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the six-month cumulative consolidated period was ¥1,262 million.」

    ¥1,262 million has been disclosed as research and development expenses for the FY2024 six-month cumulative consolidated period.
  8. FY2024-Q1Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the three-month cumulative consolidated period was ¥630 million.」

    ¥630 million has been disclosed as research and development expenses for the FY2024 three-month cumulative consolidated period.
  9. FY2023Annual R&D expenditure updateAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥2,527 million, or 4.0% of net sales, compared with ¥2,445 million, or 4.1% of net sales, in the previous consolidated fiscal year.」

    Research and development expenses for the fiscal year were ¥2,527 million, or 4.0% of net sales. The amount increased from the previous fiscal year, while the ratio to net sales declined.
  10. FY2023-Q3Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the nine-month cumulative consolidated period was ¥1,894 million.」

    ¥1,894 million has been disclosed as research and development expenses for the FY2023 nine-month cumulative consolidated period.
  11. FY2023-Q2Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the six-month cumulative consolidated period was ¥1,248 million.」

    ¥1,248 million has been disclosed as research and development expenses for the FY2023 six-month cumulative consolidated period.
  12. FY2023-Q1Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the three-month cumulative consolidated period was ¥626 million.」

    ¥626 million has been disclosed as research and development expenses for the FY2023 three-month cumulative consolidated period.
  13. FY2022Annual R&D expenditure updateAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥2,445 million, or 4.1% of net sales, compared with ¥2,472 million, or 4.7% of net sales, in the previous consolidated fiscal year.」

    Research and development expenses for the fiscal year were ¥2,445 million, or 4.1% of net sales, with both the amount and the ratio declining from the previous fiscal year.
  14. FY2022-Q3Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the nine-month cumulative consolidated period was ¥1,733 million.」

    ¥1,733 million has been disclosed as research and development expenses for the nine-month cumulative consolidated period.
  15. FY2022-Q2Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the six-month cumulative consolidated period was ¥1,163 million.」

    ¥1,163 million has been disclosed as research and development expenses for the six-month cumulative consolidated period.
  16. FY2022-Q1Cumulative R&D expenditure updateAnnual report

    「The amount of research and development activities for the Group as a whole during the three-month cumulative consolidated period was ¥566 million.」

    ¥566 million has been disclosed as research and development expenses for the three-month cumulative consolidated period.
  17. FY2021-Q3Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated third-quarter period was ¥1,838 million.」

    ¥1,838 million has been disclosed as research and development expenses for the nine-month cumulative consolidated period.
  18. FY2021-Q2Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated second-quarter period was ¥1,250 million.」

    R&D expenditure of ¥1,250 million was disclosed for the cumulative consolidated second-quarter period.
  19. FY2021-Q1Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated first-quarter period was ¥613 million.」

    R&D expenditure of ¥613 million was disclosed for the cumulative consolidated first-quarter period.
  20. FY2020-Q3Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated third-quarter period was ¥1,891 million.」

    R&D expenditure of ¥1,891 million was disclosed for the cumulative consolidated third-quarter period.
  21. FY2020-Q2Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated second-quarter period was ¥1,236 million.」

    R&D expenditure of ¥1,236 million was disclosed for the cumulative consolidated second-quarter period.
  22. FY2020-Q1Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated first-quarter period was ¥614 million.」

    R&D expenditure of ¥614 million was disclosed for the cumulative consolidated first-quarter period.
  23. FY2019Annual R&D expenditure updateAnnual report

    「R&D expenditure was ¥2,698 million in the current consolidated fiscal year, or 4.4% of sales, compared with ¥2,908 million, or 4.9% of sales, in the previous consolidated fiscal year.」

    Annual R&D expenditure was ¥2,698 million, or 4.4% of sales, down from ¥2,908 million and 4.9% of sales in the previous fiscal year.
  24. FY2019-Q3Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated third-quarter period was ¥2,069 million.」

    R&D expenditure of ¥2,069 million was disclosed for the cumulative consolidated third-quarter period.
  25. FY2019-Q2Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated second-quarter period was ¥1,393 million.」

    R&D expenditure of ¥1,393 million was disclosed for the cumulative consolidated second-quarter period.
  26. FY2019-Q1Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated first-quarter period was ¥706 million.」

    R&D expenditure of ¥706 million was disclosed for the cumulative consolidated first-quarter period.
  27. FY2018Annual R&D expenditure updateAnnual report

    「R&D expenditure was ¥2,908 million in the current consolidated fiscal year, or 4.9% of sales, compared with ¥2,668 million, or 4.7% of sales, in the previous consolidated fiscal year.」

    R&D expenditure was ¥2,908 million, or 4.9% of sales, up from ¥2,668 million in the previous fiscal year.
  28. FY2018-Q3Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated third-quarter period was ¥2,188 million.」

    R&D expenditure of ¥2,188 million was disclosed for the cumulative consolidated third-quarter period.
  29. FY2018-Q2Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated second-quarter period was ¥1,466 million.」

    R&D expenditure of ¥1,466 million was disclosed for the cumulative consolidated second-quarter period.
  30. FY2018-Q1Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated first-quarter period was ¥727 million.」

    R&D expenditure of ¥727 million was disclosed for the cumulative consolidated first-quarter period.
  31. FY2017Annual R&D expenditure updateAnnual report

    「R&D expenditure was ¥2,668 million in the current consolidated fiscal year, or 4.7% of sales, compared with ¥2,775 million, or 4.6% of sales, in the previous consolidated fiscal year.」

    Annual R&D expenditure of ¥2,668 million, or 4.7% of sales, was disclosed.
  32. FY2017-Q3Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated third-quarter period was ¥1,978 million.」

    R&D expenditure of ¥1,978 million was disclosed for the cumulative consolidated third-quarter period.
  33. FY2017-Q2Cumulative R&D expenditure updateAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated second-quarter period was ¥1,296 million.」

    R&D expenditure of ¥1,296 million was disclosed for the cumulative consolidated second-quarter period.
  34. FY2017-Q1First statedAnnual report

    「Group-wide R&D expenditure for the cumulative consolidated first-quarter period was ¥619 million.」

    R&D expenditure for the nine months ended was disclosed.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Oiles's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Quarterly R&D expenses: ¥619 million | OILES CORPORATION (6282) | Komori